On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This was the next step in BioNTech’s efforts to implement sustainable end-to-end vaccine supply solutions on the African continent.